Clinical Trials
169 trialsNCT07416188 2026-05-27
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05593094 2026-05-26
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT02696993 2026-05-20
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT06161519 2026-05-13
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT01891318 2026-05-08
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
Case Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT07569042 2026-05-06
A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma
Novelwise Pharmaceutical Corporation
Phase 1/2 Recruiting
NCT05588141 2026-05-01
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06012695 2026-04-29
NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
Novelwise Pharmaceutical Corporation
Phase 1/2 Recruiting
NCT05615623 2026-04-21
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG
InSightec
Phase 1/2 Active not recruiting
NCT05786924 2026-04-21
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Phase 1/2 Recruiting
NCT05630209 2026-04-17
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
InSightec
Phase 1/2 Active not recruiting
NCT06810544 2026-04-13
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03277638 2026-04-09
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
Case Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT06329570 2026-04-09
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
Phase 1/2 Recruiting
NCT05987644 2026-04-08
DURABLE
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT05386108 2026-04-06
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03449238 2026-03-30
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
Weill Medical College of Cornell University
Phase 1/2 Recruiting
NCT03508752 2026-03-27
Neurocognitive Decline in Patients With Brain Metastases
University of Texas Southwestern Medical Center
Phase 1/2 Active not recruiting
NCT02650401 2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT04085887 2026-03-20
Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures
Stanford University
Phase 1/2 Recruiting
NCT04789668 2026-03-18
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05660408 2026-03-09
RNA PRIME
University of Florida
Phase 1/2 Active not recruiting
NCT05789589 2026-03-04
ADORATION
Baptist Health South Florida
Phase 1/2 Recruiting
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT02942264 2026-02-23
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT03510208 2026-02-09
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Stanford University
Phase 1/2 Recruiting
NCT04478279 2026-02-09
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
Phase 1/2 Active not recruiting
NCT04923542 2026-02-06
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT05588453 2026-01-12
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04711824 2025-12-23
SOLARA
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT05256290 2025-12-09
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Black Diamond Therapeutics, Inc.
Phase 1/2 Active not recruiting
NCT04538742 2025-12-08
DB-07
AstraZeneca
Phase 1/2 Active not recruiting
NCT06194929 2025-12-03
DETERMINE
University of Utah
Phase 1/2 Recruiting
NCT07206498 2025-11-28
WAYWIN103
Wayshine Biopharm, Inc.
Phase 1/2 Recruiting
NCT02285439 2025-10-07
Study of MEK162 for Children With Low-Grade Gliomas
Children's Hospital Los Angeles
Phase 1/2 Completed
NCT07177950 2025-09-17
A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases
Peking University Cancer Hospital & Institute
Phase 1/2 Not yet recruiting
NCT04977375 2025-09-03
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Cedars-Sinai Medical Center
Phase 1/2 Recruiting
NCT01478178 2025-08-29
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Kintara Therapeutics, Inc.
Phase 1/2 Completed
NCT06907043 2025-08-19
EIK1004-001
Eikon Therapeutics
Phase 1/2 Recruiting
NCT04121455 2025-06-25
GLORIA
TME Pharma AG
Phase 1/2 Active not recruiting
NCT02521051 2025-05-13
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Massachusetts General Hospital
Phase 1/2 Terminated
NCT05664243 2025-05-01
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
In8bio Inc.
Phase 1/2 Active not recruiting
NCT05535413 2025-04-25
UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases
Hunan Cancer Hospital
Phase 1/2 Recruiting
NCT02861898 2025-04-09
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Northwell Health
Phase 1/2 Recruiting
NCT03213002 2025-04-09
CAPTEM
Northwell Health
Phase 1/2 Recruiting
NCT05669352 2025-04-04
A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases
University of Florida
Phase 1/2 Suspended
NCT01906385 2025-03-26
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Plus Therapeutics
Phase 1/2 Recruiting
NCT03046992 2025-03-21
Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC
Yuhan Corporation
Phase 1/2 Completed
NCT03150862 2025-02-04
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
BeiGene
Phase 1/2 Completed